普通外文研报
Estimating Unmitigated Impact of CY26 Star Ratings Recalculations; Reit OW ALHC, CVS, UNH
研报英文原文证据摘录
Estimating Unmitigated Impact of CY26 Star Ratings Recalculations; Reit OW ALHC, CVS, UNH
ere recalculations degrade Star Ratings, contracts
can remain at initial CY26 Star Ratings levels and retain associated CY27 QBP status.
• Our work suggests that recalculation would only increase CY26 Star Ratings for
29 contracts covering 913.12K lives or approximately 2.55% of the MA market. See
Exhibit 21. Absent CMS' hold harmless provision, we estimate that recalculation would
lower the overall MA market's enrollment weighted average CY26 Star Rating by (0.34)
from an initial 4.03 to a revised 3.69. Our initial 4.03 weighted average CY26 Star Rating
is approximately in-line with the 3.98 reported by CMS on the CY26 Star Ratings Fact
Sheet. We use each contract's initial CY26 Part C measure scores, Part C measure
weights, Part C CAI category, Part C CAI value and Part C summary rating to estimate its
initial CY26 Part C reward factor. Excel available on request. To recalculate CY26 Star
Ratings, we remove the 18 measures described in the HPMS memo (and listed in Exhibit
8); apply unchanged weights to the surviving Part C measures; assume initial CY26
Part C CAI category is unchanged; apply the new CAI value that corresponds to initial
category; add the contract's initial CY26E Part C reward factor; and round according
to CMS rules. We arrive at adjusted CY26E Star Ratings by contract. We compare
each contract's adjusted CY26E Star Ratings (contemplating only Part C measures,
adjustments and rewards) to its initial CY26 Star Rating (contemplating Parts C and D
measures, adjustments and rewards).
• We expect most ALHC, CVS, HUM and UNH contracts to remain at initial CY26
Star Ratings and retain associated CY27 QBP status. We estimate the unmitigated
本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。
打开研报阅读器